首页> 外文OA文献 >Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain

【2h】

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain

机译：非索罗定，托特罗定或索非那新在西班牙初级保健机构中作为膀胱过度活动症首次治疗的健康经济学视角

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain [J] . Antoni Sicras-Mainar, Javier Rejas, Ruth Navarro-Artieda, BMC Urology . 2013,第1期

机译：非索罗定，托特罗定或索非那新在西班牙初级保健机构中作为膀胱过度活动症综合征首次治疗的健康经济学视角
2. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service [J] . Linda Cardozo Andrew Thorpe Juliet Warner, Linda Cardozo Andrew Thorpe Juliet Warner BJU International . 2010,第4期

机译：在英国国家卫生服务局治疗索非那定与非索罗定，奥昔布宁立即释放，丙氧维林，托特罗定延长释放和托特罗定立即释放在膀胱过度活动症患者中的成本效益
3. THE COST-EFFECTIVENESS OF SOLIFENACIN VS FESOTERODINE, OXYBUTYNIN IMMEDIATE-RELEASE, PROPIVERINE, TOLTERODINE EXTENDED-RELEASE AND TOLTERODINE IMMEDIATE-RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UK NATIONAL HEALTH SERVICE [J] . Juliet L. Warner BJU International . 2010,第4期

机译：索非那宁比索非丁定，奥昔布宁立即释放，异丙肾上腺素，托罗替丁延长释放和托罗替丁立即释放在英国国家卫生服务部门活动过度的患者中的成本效益
4. Development of an active agent carrying, biodegradable implant for the intravesical therapy of the overactive bladder syndrome [C] . Walter Michaeli, Dipl.-Ing. Ina Michaelis, Joachim Grosse, Annual technical conference of the Society of Plastics Engineers;Technical conference of the Society of Plastics Engineers;ANTEC 2009 . 2011

机译：携带活性剂的可生物降解植入物的开发，用于膀胱过度活动综合征的膀胱内治疗
5. Medication-Related Burden Among Patients with Chronic Disease Conditions: Perspectives of Patients Attending Non-Communicable Disease Clinics in a Primary Healthcare Setting in Qatar [D] . Zidan, Amani. 2017

机译：慢性病患者中与药物相关的负担：卡塔尔初级卫生保健机构就诊非传染性疾病患者的观点
6. Health economics perspective of fesoterodine tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain [O] . Antoni Sicras-Mainar, Javier Rejas, Ruth Navarro-Artieda, 2013

机译：非索罗定托特罗定或索非那新在西班牙初级保健机构中作为膀胱过动症综合治疗的首次疗法的健康经济学视角
7. PUK11 UPDATED ECONOMIC ANALYSIS OF FESOTERODINE RELATIVE TO TOLTERODINE AND SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER: THE SWEDISH PERSPECTIVE [O] . Lee R., Snedecor S.J., Kvasz M.G., 2011

机译：PUK11有关替托罗定和索非那宁治疗过活性膀胱的费斯托尔定的最新经济分析：瑞典语观点

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain

著录项

引文网络

相似文献

相关主题

期刊订阅